

## Pleiotropic and Other Genetic Effects Influencing the Activities of Brain and Liver Enzymes in Congenic Lines of C57BL/6J Mice with Defined Electrophoretic Variant Markers

Ritchie J. Feuers,<sup>1</sup> Jack B. Bishop,<sup>1</sup> Lynda J. McGarrity,<sup>1</sup> Olen E. Doman,<sup>1</sup> Robert R. Delongchamp,<sup>1</sup> and Thomas H. Roderick<sup>2</sup>

Received 21 Apr. 1982—Final 2 June 1982

---

*A single genetic factor may affect the realization of several enzymes. To investigate the extent of pattern pleiotropy in the mouse, the activities of 28 enzymes in livers and brains from an inbred stock of C57BL/6JNctr and five F<sub>1</sub> stocks heterozygous for known electrophoretic variants were measured. Five congenic backcross stocks of C57BL/6J, each homozygous for one or more electrophoretic markers, were mated with C57BL/6JNctr to construct the heterozygous variant F<sub>1</sub> stocks. One of the five F<sub>1</sub> stocks had no enzyme activities significantly different from those of C57BL/6JNctr, while two had one enzyme, one had four enzymes, and another had six enzymes with activities that were significantly different from those of C57BL/6JNctr. The latter two F<sub>1</sub> stocks with multiple activity differences were those having the largest proportion of their genome of donor origin. Two of the F<sub>1</sub> stocks were different from each other for one enzyme, and two were different for another enzyme. These differences and the relationship of these enzyme activities to the variant genes suggest that several genetic factors may affect an enzyme's realization.*

---

**KEY WORDS:** enzymes; congenic; pleiotropy; genetic factor.

This work was supported by the National Center for Toxicological Research and by Contract EV-76-S-02-3267 with the Department of Energy, Grant GM-19656 from the National Institute of General Medical Sciences, and Contract ES-42159 with the National Institute of Environmental Health Sciences.

<sup>1</sup> Department of Health and Human Services, Food and Drug Administration, National Center for Toxicological Research, Jefferson, Arkansas 72079.

<sup>2</sup> Jackson Laboratory, Bar Harbor, Maine 04609.

## INTRODUCTION

The expression of an enzyme's ultimate phenotype is dependent upon a complex set of processes involved in its realization (Paigen, 1971). Genetic control over these processes by structural, regulatory, temporal, or processing genes has been described and reviewed (Paigen, 1979). This suggests that multiple genetic factors influence the final expression of a realized enzyme. Modification of any one of these factors could result in alteration of that enzyme's activity.

A single genetic factor may also affect the realization of several enzymes. For example, posttransplantational sialylation of several acid hydrolases (Lally and Shows, 1977; Womack and Eicher, 1977; Dizik and Elliot, 1978), expressed as changes in enzyme activity, has been attributed to pleiotropic effects of a single neurominidase (Neu-1) gene (Womack *et al.*, 1981). If such effects play a role in the realization of many enzymes, then most defined structural gene alterations might be expected to modify the activity of other enzymes.

A backcross project has made available 13 stocks of C57BL/6J mice which carry alterations of defined structural genes (Roderick and Womack, 1981). The influence which a heterozygous variant genome of C57BL/6J has upon the activities of 28 brain and liver enzymes, relative to their activities in inbred C57BL/6JNctr mice, has been investigated using 5 of these stocks.

## MATERIALS AND METHODS

An inbred stock of C57BL/6JNctr and five congenic backcross stocks of C57BL/6J, designated BC2, BC6A, BC7, BC10, and BC13, were used in this study (Table I). The allelic variants of the congenic line of BC2 were agouti

**Table I.** Allelic Variants on C57BL/6J Background

| Line | Locus <sup>a</sup> | Chromosome | C57BL/6J allele | New allele            | Strain of origin |
|------|--------------------|------------|-----------------|-----------------------|------------------|
| BC2  | <i>a</i>           | 2          | <i>a</i>        | <i>a</i> <sup>+</sup> | CE/J             |
|      | <i>Amy-1</i>       | 3          | <i>a</i>        | <i>b</i>              | CE/J             |
|      | <i>Amy-2</i>       | 3          | <i>a</i>        | <i>b</i>              | CE/J             |
| BC6A | <i>Gdc-1</i>       | 15         | <i>b</i>        | <i>d</i>              | Castaneus        |
| BC7  | <i>Mor-1</i>       | 5          | <i>a</i>        | <i>b</i>              | MOR stock        |
| BC10 | <i>Es-10</i>       | 14         | <i>a</i>        | <i>c</i>              | Molossinus       |
|      | <i>Np-1</i>        | 14         | <i>a</i>        | <i>b</i>              | Molossinus       |
| BC13 | <i>Es-8</i>        | 7          | <i>a</i>        | <i>b</i>              | Castaneus        |

<sup>a</sup>*Amy-1* and *-2*, amylase genes; *Gdc-1*, glyceraldehyde decarboxylase gene; *Mor-1*, Malate dehydrogenase gene; *Es-8* and *-10*, Esterase genes; *Np-1*, Nucleoside phosphorylase gene.

( $a^+$ ) and two amylases (*Amy-1<sup>b</sup>* and *Amy-2<sup>b</sup>*). All were derived from CE/J. The variants in line BC10 were an esterase (*Es-10<sup>c</sup>*) and a nucleoside phosphorylase (*Np-1<sup>b</sup>*), both derived from the interfertile subspecies *Mus musculus molossinus*. The variant in congenic line BC6A was glycerol phosphate dehydratase (*Gdc-1<sup>d</sup>*), and the variant in BC13 was another esterase (*Es-8<sup>b</sup>*), each from another interfertile subspecies, *Mus musculus castaneus*. The variant in BC7 was mitochondrial malate dehydrogenase (*Mor-1<sup>b</sup>*) from the MOR stock originally isolated from *Mus musculus molossinus*. Each marker, supposedly having arisen as a spontaneous mutation in the donor stock, was individually transferred to the C57BL/6J background by backcrossing through at least nine generations. For ease of maintenance, the last backcross generation of each congenic stock was intercrossed to make the respective congenic strains homozygous for the variant markers.

Homozygous mice from each of the five congenic stocks were mated to C57BL/6JNctr mice when they became 6 weeks of age, to produce approximately 50  $F_1$  heterozygotes per stock (designated BC2 $F_1$ , BC6A $F_1$ , BC7 $F_1$ , BC10 $F_1$ , and BC13 $F_1$ ). At the same time, matings of C57BL/6JNctr mice were established to produce 50 males and 50 females of the inbred stock. All matings provided 5–10 individuals from each group born within a given week. The mice were randomly distributed among seven experimental blocks in such a way that each block was evenly represented by an equal ratio of mice from each stock. These blocks became sacrifice, tissue preparation, and enzyme activity analysis units. This design allowed for comparisons of enzyme activities across and within the blocks, eliminating differences which might result from sacrifice, tissue preparation, or analysis phenomena. Thus, the potential for identification of relatively small activity differences was maximized.

When mice became 10 weeks old, cages containing three to five mice were retrieved individually from the animal room with care taken to minimize disturbance of remaining animals. All mice within a particular cage were decapitated in an adjacent room within 10–15 sec. Brain and liver tissues were surgically removed, wrapped in aluminum foil, and frozen in liquid nitrogen. All mice within a block were killed in a similar manner within a 60-min period (1:00–2:00 pm CST). Tissues were retrieved from the liquid nitrogen and stored at  $-70^\circ\text{C}$  to await preparation and analysis. Tissue preparations and analyses were performed by blocks according to our standard procedures (Feuers *et al.*, 1980). The enzymes analyzed from brain were adenylate kinase (AK), pyruvate kinase (PK), malate dehydrogenase (MDH), adenosine triphosphate (ATPase), creatine phosphokinase (CPK), phosphoglucose isomerase (PGI), creatininase (CR), and succinate thiokinase (STK). The enzymes analyzed in the liver were glutamate oxaloacetate transaminase

(GOT), citrate cleavage enzyme (CCE), isocitrate dehydrogenase (ICD), glutathione reductase (GR), glycerokinase (GK), glutamate dehydrogenase (GIDH), cytochrome *c* reductase (CCR), glyoxalate reductase (GlyR), alanine aminotransferase (GPT), amino acid oxidase (AAO), serine dehydratase (SDH), sorbitol dehydrogenase (SbDH), alcohol dehydrogenase (ADH), malic enzyme (ME), fatty acid synthetase (FAS), fructose diphosphatase (FDPase), lactate dehydrogenase (LDH), fructose diphosphate aldolase (FDP,Ald), fructose-1-phosphate aldolase (F1P,Ald), and pyruvate decarboxylase (PDC).

The activity data were sorted by computer from coded entry and collated according to block, variant stock, and sex. Mean activities, standard deviations, and coefficients of variation (CV) were calculated. A one-way analysis of variance was performed for each sex and enzyme, and differences were delineated using Duncan's multiple-range test (Winer, 1971). A difference between two stocks was considered significant if the analyses of variance were significant at the 0.1 level in both sexes for the enzyme. Since these analyses of variance for each sex are independent, this criterion results in a significance level for stock differences of  $\leq 0.01$  for the enzyme.

Partial correlation coefficients corrected for sex and strain were calculated (Kshirsagar, 1972). A factor analysis (Seal, 1968) was performed for those multiple enzyme differences observed within stocks to estimate the minimum number of factors which could account for any observed partial correlations.

## RESULTS

Thus far we have examined the activities of 28 enzymes in stocks of C57BL/6JNctr mice and  $F_1$  mice produced from matings of this inbred with 5 of the 13 available congenic lines. The mean activities and CVs for all enzymes for each stock are listed in Table II. The CVs for C57BL/6JNctr mice are relatively low and range from 0.02 for CPK in males to 0.39 for SDH in females. Only AAO (0.38, females; 0.37, males), CCE (0.32, females), SDH (0.39, females), and STK (0.27, females) have CV values above 25%. The CVs for enzymes measured in the  $F_1$  stocks are similar to those of C57BL/6JNctr.

Many statistically significant differences among enzyme activities were obtained (Table II). Although most of these involved differences in only one sex, several differences were below the required 0.1 level for both sexes. In fact, of those with differences for both sexes, only AAO males ( $P = 0.06$ ) and GK females ( $P = 0.06$ ) were above 0.05. Differences among stocks were found for the enzymes AAO, GIDH, GK, F1P,Ald, ATPase, CR, MDH, STK, and FDP,Ald (Table III). The activities of CR were different in

**Table II.** Comparisons of Mean Enzyme Activities Among Stocks<sup>a,b</sup>

| Brain enzyme | Sex      | C57BL/6JNctr act (cv)      | BC10F <sub>1</sub> act (cv)     | BC13F <sub>1</sub> act (cv)    | BC2F <sub>1</sub> act (cv)     | BC6AF <sub>1</sub> act (cv) | BC7F <sub>1</sub> act (cv)     |
|--------------|----------|----------------------------|---------------------------------|--------------------------------|--------------------------------|-----------------------------|--------------------------------|
| Brain Enzyme | AK       | F 4731 (.07)               | 4940 (.09)                      | 4802 (.07)                     | 4814 (.12)                     | 4834 (.06)                  | 4645 (.05)                     |
|              | M        | 4731 (.07)                 | 4877 (.05)                      | 4949 (.06)                     | 4842 (.09)                     | 4643 (.11)                  | 4697 (.05)                     |
|              | ATPase   | F 460 (.17) <sup>c</sup>   | <b>544</b> (.16) <sup>a</sup>   | 496 (.17) <sup>bc</sup>        | 499 (.16) <sup>abc</sup>       | 509 (.14) <sup>ab</sup>     | 466 (.15) <sup>bc</sup>        |
|              | M        | 448 (.19) <sup>c</sup>     | <b>542</b> (.16) <sup>a</sup>   | 518 (.18) <sup>ab</sup>        | 516 (.17) <sup>ab</sup>        | 474 (.15) <sup>bc</sup>     | 487 (.15) <sup>bc</sup>        |
|              | CPK      | F 1692 (.03)               | 1691 (.02)                      | 1693 (.02)                     | 1681 (.02)                     | 1702 (.03)                  | 1708 (.03)                     |
|              | M        | 1695 (.02)                 | 1697 (.03)                      | 1710 (.03)                     | 1697 (.03)                     | 1687 (.03)                  | 1703 (.02)                     |
|              | CR       | F 602 (.20) <sup>b</sup>   | <b>684</b> (.15) <sup>a</sup>   | 602 (.17) <sup>b</sup>         | 625 (.23) <sup>ab</sup>        | 684 (.14) <sup>a</sup>      | 585 (.15) <sup>b</sup>         |
|              | M        | 617 (.15) <sup>c</sup>     | <b>675</b> (.13) <sup>ab</sup>  | 707 (.16) <sup>a</sup>         | 683 (.16) <sup>ab</sup>        | 634 (.16) <sup>bc</sup>     | 632 (.16) <sup>bc</sup>        |
|              | MDH      | F 33608 (.09) <sup>b</sup> | <b>35744</b> (.06) <sup>a</sup> | 34366 (.08) <sup>ab</sup>      | 33520 (.08) <sup>b</sup>       | 35291 (.08) <sup>a</sup>    | 33468 (.05) <sup>b</sup>       |
|              | M        | 32836 (.09) <sup>c</sup>   | <b>35560</b> (.05) <sup>a</sup> | 35580 (.07) <sup>a</sup>       | 34399 (.08) <sup>ab</sup>      | 33624 (.11) <sup>bc</sup>   | 34378 (.05) <sup>ab</sup>      |
|              | PGI      | F 4237 (.03)               | 4275 (.03)                      | 4260 (.03)                     | 4253 (.03)                     | 4270 (.02)                  | 4241 (.03)                     |
|              | M        | 4224 (.04)                 | 4280 (.02)                      | 4298 (.03)                     | 4248 (.04)                     | 4229 (.04)                  | 4249 (.02)                     |
| Liver Enzyme | PK       | F 14359 (.07)              | 14367 (.06)                     | 14417 (.08)                    | 14058 (.09)                    | 14546 (.07)                 | 13947 (.08)                    |
|              | M        | 13988 (.11)                | 14229 (.05)                     | 14452 (.06)                    | 14263 (.09)                    | 14006 (.10)                 | 14110 (.05)                    |
|              | STK      | F 750 (.27) <sup>c</sup>   | <b>942</b> (.18) <sup>a</sup>   | 798 (.27) <sup>bc</sup>        | 788 (.22) <sup>bc</sup>        | 860 (.20) <sup>ab</sup>     | 760 (.20) <sup>bc</sup>        |
|              | M        | 747 (.23) <sup>d</sup>     | <b>939</b> (.21) <sup>a</sup>   | 878 (.24) <sup>ab</sup>        | 877 (.23) <sup>abc</sup>       | 789 (.18) <sup>bcd</sup>    | 766 (.21) <sup>cd</sup>        |
|              | AAO      | F 273 (.38) <sup>b</sup>   | 314 (.27) <sup>ab</sup>         | 307 (.21) <sup>ab</sup>        | <b>352</b> (.36) <sup>a</sup>  | 304 (.28) <sup>ab</sup>     | 310 (.26) <sup>ab</sup>        |
|              | M        | 217 (.37) <sup>b</sup>     | 249 (.25) <sup>ab</sup>         | 260 (.23) <sup>ab</sup>        | <b>267</b> (.38) <sup>a</sup>  | 255 (.33) <sup>ab</sup>     | 261 (.20) <sup>ab</sup>        |
|              | ADH      | F 198 (.13)                | 203 (.09)                       | 193 (.10)                      | 190 (.10)                      | 194 (.13)                   | 198 (.20)                      |
|              | M        | 169 (.09) <sup>a</sup>     | 173 (.09) <sup>a</sup>          | 170 (.09) <sup>a</sup>         | 151 (.12) <sup>b</sup>         | 165 (.10) <sup>a</sup>      | 170 (.12) <sup>a</sup>         |
|              | CCE      | F 285 (.32)                | 294 (.18)                       | 299 (.17)                      | 308 (.32)                      | 294 (.27)                   | 287 (.24)                      |
|              | M        | 232 (.25)                  | 258 (.25)                       | 271 (.19)                      | 245 (.25)                      | 254 (.27)                   | 268 (.22)                      |
|              | CCR      | F 1331 (.18) <sup>a</sup>  | 1280 (.09) <sup>a</sup>         | 1248 (.12) <sup>ab</sup>       | 1153 (.11) <sup>b</sup>        | 1270 (.16) <sup>a</sup>     | 1241 (.19) <sup>ab</sup>       |
|              | M        | 904 (.13)                  | 868 (.24)                       | 901 (.17)                      | 928 (.19)                      | 932 (.29)                   | 846 (.15)                      |
| Liver Enzyme | FAS      | F 261 (.09)                | 266 (.10)                       | 263 (.10)                      | 251 (.09)                      | 259 (.09)                   | 264 (.10)                      |
|              | M        | 275 (.08) <sup>bc</sup>    | 282 (.08) <sup>ab</sup>         | 282 (.09) <sup>ab</sup>        | 263 (.11) <sup>c</sup>         | 272 (.08) <sup>bc</sup>     | 288 (.09) <sup>a</sup>         |
|              | FDPase   | F 175 (.14)                | 179 (.11)                       | 178 (.13)                      | 172 (.12)                      | 178 (.11)                   | 179 (.11)                      |
|              | M        | 142 (.10)                  | 149 (.11)                       | 153 (.13)                      | 141 (.20)                      | 145 (.13)                   | 147 (.14)                      |
|              | FDP, Ald | F 364 (.15) <sup>a</sup>   | <b>325</b> (.19) <sup>b</sup>   | 343 (.19) <sup>ab</sup>        | <b>314</b> (.20) <sup>b</sup>  | 343 (.16) <sup>ab</sup>     | 347 (.17) <sup>ab</sup>        |
|              | M        | 389 (.14) <sup>a</sup>     | <b>352</b> (.20) <sup>bc</sup>  | 379 (.14) <sup>ab</sup>        | <b>339</b> (.21) <sup>c</sup>  | 373 (.11) <sup>abc</sup>    | 377 (.14) <sup>ab</sup>        |
|              | FIP, Ald | F 933 (.08)                | 896 (.08)                       | 909 (.07)                      | 906 (.08)                      | 922 (.07)                   | 919 (.07)                      |
|              | M        | 976 (.08) <sup>a</sup>     | 928 (.09) <sup>b</sup>          | 942 (.06) <sup>ab</sup>        | 922 (.09) <sup>b</sup>         | 942 (.06) <sup>ab</sup>     | 942 (.07) <sup>ab</sup>        |
|              | GIDH     | F 2033 (.16) <sup>b</sup>  | <b>2296</b> (.15) <sup>a</sup>  | <b>2238</b> (.11) <sup>a</sup> | <b>2315</b> (.20) <sup>a</sup> | 2057 (.15) <sup>b</sup>     | <b>2266</b> (.12) <sup>a</sup> |
|              | M        | 1661 (.15) <sup>b</sup>    | <b>1949</b> (.11) <sup>a</sup>  | <b>1915</b> (.13) <sup>a</sup> | <b>1962</b> (.18) <sup>a</sup> | 1824 (.14) <sup>a</sup>     | <b>1948</b> (.12) <sup>a</sup> |
|              | Gik      | F 440 (.24) <sup>b</sup>   | 497 (.25) <sup>a</sup>          | 486 (.21) <sup>a</sup>         | <b>516</b> (.28) <sup>a</sup>  | 466 (.22) <sup>ab</sup>     | 476 (.20) <sup>ab</sup>        |
|              | M        | 380 (.21) <sup>b</sup>     | 431 (.20) <sup>a</sup>          | 445 (.20) <sup>a</sup>         | <b>437</b> (.26) <sup>a</sup>  | 417 (.22) <sup>ab</sup>     | 428 (.26) <sup>ab</sup>        |
|              | GlyR     | F 16716 (.08)              | 16538 (.06)                     | 16406 (.08)                    | 16245 (.06)                    | 16448 (.06)                 | 16256 (.05)                    |
| Liver Enzyme | M        | 17627 (.07)                | 17253 (.08)                     | 17380 (.09)                    | 17175 (.06)                    | 17815 (.07)                 | 18053 (.08)                    |
|              | GOT      | F 11216 (.09)              | 11172 (.08)                     | 11519 (.11)                    | 11756 (.11)                    | 11451 (.09)                 | 11776 (.10)                    |
|              | M        | 9355 (.09)                 | 10004 (.11)                     | 10552 (.11)                    | 10108 (.12)                    | 10129 (.19)                 | 10667 (.14)                    |
|              | GPT      | F 2527 (.10)               | 2480 (.11)                      | 2489 (.13)                     | 2473 (.13)                     | 2453 (.13)                  | 2522 (.12)                     |
|              | M        | 2161 (.09)                 | 2117 (.09)                      | 2236 (.13)                     | 2088 (.16)                     | 2152 (.13)                  | 2182 (.09)                     |
|              | GR       | F 503 (.07)                | 502 (.04)                       | 493 (.09)                      | 494 (.06)                      | 494 (.06)                   | 496 (.08)                      |
|              | M        | 550 (.08) <sup>b</sup>     | 565 (.06) <sup>ab</sup>         | 562 (.06) <sup>ab</sup>        | 539 (.09) <sup>ab</sup>        | 547 (.08) <sup>b</sup>      | 576 (.09) <sup>a</sup>         |
|              | ICD      | F 3342 (.10)               | 3353 (.10)                      | 3330 (.11)                     | 3330 (.11)                     | 3205 (.14)                  | 3379 (.11)                     |
|              | M        | 3149 (.13) <sup>a</sup>    | 3108 (.14) <sup>ab</sup>        | 3236 (.10) <sup>a</sup>        | 2923 (.13) <sup>b</sup>        | 3086 (.10) <sup>ab</sup>    | 3321 (.15) <sup>a</sup>        |
|              | LDH      | F 22847 (.13)              | 22454 (.15)                     | 21853 (.15)                    | 21804 (.11)                    | 21859 (.13)                 | 22193 (.14)                    |
|              | M        | 24268 (.09) <sup>a</sup>   | 24147 (.14) <sup>a</sup>        | 23806 (.14) <sup>ab</sup>      | 22319 (.11) <sup>a</sup>       | 24209 (.11) <sup>a</sup>    | 25159 (.13) <sup>a</sup>       |
|              | ME       | F 323 (.21)                | 344 (.23)                       | 334 (.20)                      | 312 (.20) <sup>c</sup>         | 301 (.27)                   | 331 (.22)                      |
|              | M        | 359 (.25) <sup>a</sup>     | 399 (.25) <sup>a</sup>          | 372 (.25) <sup>a</sup>         | 286 (.39) <sup>c</sup>         | 301 (.33) <sup>bc</sup>     | 348 (.21) <sup>ab</sup>        |
| Liver Enzyme | PDC      | F 10841 (.10)              | 10620 (.10)                     | 10685 (.11)                    | 10613 (.09)                    | 10565 (.09)                 | 10616 (.09)                    |
|              | M        | 11324 (.06)                | 11255 (.08)                     | 11300 (.09)                    | 10949 (.10)                    | 11224 (.07)                 | 11746 (.08)                    |
|              | SbDH     | F 2002 (.09)               | 1952 (.09)                      | 1931 (.11)                     | 1913 (.13)                     | 1989 (.10)                  | 1976 (.11)                     |
|              | M        | 1887 (.09) <sup>a</sup>    | 1931 (.11) <sup>a</sup>         | 1900 (.08) <sup>a</sup>        | 1744 (.11) <sup>b</sup>        | 1772 (.09) <sup>b</sup>     | 1846 (.09) <sup>ab</sup>       |
|              | SDH      | F 630 (.39)                | 556 (.21)                       | 613 (.24)                      | 596 (.36)                      | 616 (.44)                   | 646 (.23)                      |
|              | M        | 404 (.18)                  | 413 (.21)                       | 438 (.31)                      | 451 (.39)                      | 478 (.48)                   | 469 (.22)                      |

<sup>a</sup>Activity (Act) =  $\mu$ moles NAD<sup>+</sup>/h/g tissue; Coefficient of variation (cv) = standard deviation/mean activity a, b, c, d similarity indicates non-significant differences (P > 0.05) between activities among stocks for a sex.

<sup>b</sup>Bold type indicates F<sub>1</sub> activities which are significantly different (P < 0.01) from C57BL/6JNctr for both sexes.

Sample Sizes: C57BL/6JNctr  $\varphi$  = 51  $\delta$  = 45. BC10F<sub>1</sub>  $\varphi$  = 24  $\delta$  = 28.

BC13F<sub>1</sub>  $\varphi$  = 30

$\delta$  = 28. BC2F<sub>1</sub>  $\varphi$  = 21.  $\delta$  = 25. BC6AF<sub>1</sub>  $\varphi$  = 29  $\delta$  = 27.

BC7F<sub>1</sub>  $\varphi$  = 23  $\delta$  = 24

**Table III.** Relative Deviation in Activity for Those Enzymes of Congenic Lines Where Both Males and Females Were Significantly Different from C57BL/6JNctr

| F <sub>1</sub> congenic line | Enzyme                         | % Difference from C57BL/6JNctr <sup>a</sup> |
|------------------------------|--------------------------------|---|
| BC2                          | Amino acid oxidase             | +26%  |
|                              | Glutamate dehydrogenase        | +16%  |
|                              | Glycerokinase                  | +16%  |
|                              | Fructose diphosphate, Aldolase | -14%  |
| BC6A                         | —                              | —   |
| BC7                          | Glutamate dehydrogenase        | +14%  |
| BC10                         | Adenosine triphosphatase       | +20%  |
|                              | Creatininase                   | +11%  |
|                              | Glutamate dehydrogenase        | +10%  |
|                              | Malate dehydrogenase           | +10%  |
|                              | Succinate thiokinase           | +26%  |
|                              | Fructose diphosphate, Aldolase | -10%  |
| BC13                         | Glutamate dehydrogenase        | +13%  |

<sup>a</sup>(+) and (-): Indicates percent increase or decrease in an enzymes activity as an average of males and females from an F<sub>1</sub> stock relative to C57BL/6JNctr.

BC6AF<sub>1</sub> and BC13F<sub>1</sub>, while the activities of STK were different in BC10F<sub>1</sub> and BC2F<sub>1</sub>. The enzyme activities of ATPase, CR, GIDH, MDH, STK, and FDP,Ald in BC10F<sub>1</sub> were found to be different from those in C57BL/6JNctr mice, and the activities of AAO, GIK, GIDH, and FDP,Ald in the BC2F<sub>1</sub> stock were found to be different from those in C57BL/6JNctr mice. The activity of GIDH in C57BL/6JNctr mice was also different from the activities found in both BC13F<sub>1</sub> and BC7F<sub>1</sub> stocks. No significant differences were observed in across-block comparisons among any stocks. None of the enzymes in the BC6AF<sub>1</sub> stock were distinguishable from those in C57BL/6JNctr for both males and females. The BC10F<sub>1</sub> carrying two known allelic variants and the BC2F<sub>1</sub> carrying three known allelic variants were the only stocks from which multiple enzyme activity changes were observed.

The six enzymes of BC10F<sub>1</sub> and the four enzymes of BC2F<sub>1</sub> which were different from C57BL/6JNctr represent a total of eight variant enzymes, with two common to both stocks. Several partial correlations were found among these eight enzymes (Table IV). Factor analysis identified three association groups: ATPase, CR, MDH, and STK are one group; AAO, GIK, and GIDH are another; and FDP,Ald seems to be unrelated to either group. Association between enzymes implies that they are causatively dependent or that they are interrelated through some common factor(s). With the exception of FDP,Ald, the enzyme variants of the F<sub>1</sub> stocks were higher than those of C57BL/6JNctr. Glutamate dehydrogenase activity was different from that of C57BL/6JNctr for all the heterozygous stocks except BC6AF<sub>1</sub>.

Table IV. Partial Correlation Coefficients and Significance Levels

|   | BC10F <sub>1</sub> <sup>a</sup> |        |        |         | BC2F <sub>1</sub> <sup>a</sup> |        |        |     |     |
|---|---------------------------------|--------|--------|---------|--------------------------------|--------|--------|-----|-----|
|   | STK                             | MDH    | ATPase | CR      | FDP,Ald                        | GIDH   |        | AAO | GIK |
|   |                                 |        |        |         |                                |        |        |     |     |
| Glycerokinase (GIK)                     | 0.0298                          | 0.1082 | 0.0983 | 0.0426  | 0.1956                         | 0.7502 | 0.7689 | —   | —   |
| Amino Acid oxidase (AAO)                | 0.5821                          | 0.0450 | 0.0685 | 0.4314  | 0.0003                         | 0.0001 | 0.0001 | —   | —   |
|   | -0.0239                         | 0.1174 | 0.0786 | -0.0052 | 0.2388                         | 0.7408 | —      | —   | —   |
| Glutamate Dehydrogenase (GIDH)          | 0.6587                          | 0.0295 | 0.1459 | 0.9238  | 0.0001                         | 0.0001 | —      | —   | —   |
|   | 0.0057                          | 0.0598 | 0.1041 | 0.0383  | 0.1945                         | —      | —      | —   | —   |
| Fructose diphosphate aldolase (FDP,Ald) | 0.9158                          | 0.2688 | 0.0537 | 0.4790  | 0.0003                         | —      | —      | —   | —   |
|   | 0.0635                          | 0.1031 | 0.1404 | 0.0692  | —                              | —      | —      | —   | —   |
| Creatininase (CR)                       | 0.2399                          | 0.0560 | 0.0091 | 0.2002  | —                              | —      | —      | —   | —   |
|   | 0.7287                          | 0.4297 | 0.6280 | —       | —                              | —      | —      | —   | —   |
| Adenosine triphosphatase (ATPase)       | 0.0001                          | 0.0001 | 0.0001 | —       | —                              | —      | —      | —   | —   |
|   | 0.7534                          | 0.6558 | —      | —       | —                              | —      | —      | —   | —   |
| Malate dehydrogenase (MDH)              | 0.0001                          | 0.0001 | —      | —       | —                              | —      | —      | —   | —   |
|   | 0.4738                          | —      | —      | —       | —                              | —      | —      | —   | —   |
| Succinate Thiokinase (STK)              | 0.0001                          | —      | —      | —       | —                              | —      | —      | —   | —   |
|   | —                               | —      | —      | —       | —                              | —      | —      | —   | —   |

<sup>a</sup>Enzymes selected for analysis were those variant in BC10F<sub>1</sub> and BC2F<sub>1</sub> stocks, each of which had multiple enzyme differences from C57BL/6JNctr.

## DISCUSSION

The mating scheme used in this study provided  $F_1$  stocks which differed from each other and from C57BL/6JNctr only for those portions of the congenic stock genome which might be heterozygous with respect to that of C57BL/6JNctr. Because of the methods by which the congenic stocks were developed, sublines of C57BL/6J mice comparable to the individual congenic stocks but without the marker genes were not available. The use of a single inbred subline, C57BL/6JNctr, in the production of all  $F_1$  stocks minimizes the effects of subline variability for comparisons among  $F_1$  stocks and between  $F_1$  stocks and C57BL/6JNctr mice. However, it does not permit us to unequivocally ascribe observed differences to the specific electrophoretic variant markers. Rather, it allows us to test for the effect of heterogeneity resulting from differences in the genome of congenic stocks and C57BL/6JNctr upon enzyme activity levels. In addition to the electrophoretic variant allele(s) of the congenic stock, such differences may also include an allele(s) from the donor strain that was closely linked to, and segregated with, the marker allele during the backcrossing process used to construct the congenic stock; an allele(s) from the donor strain that was not linked to the marker allele but was transmitted to the congenic stock simply by chance; and a variant allele(s) of C57BL/6J which, through genetic drift (Hoi-Sen, 1972; Festing, 1973; Bailey, 1977; Papaionnou and Festing, 1980), has become fixed either in the C57BL/6J sublines used to construct the congenic stocks or in the C57BL/6JNctr used to produce the  $F_1$  stocks.

Enzyme activity comparisons among all stocks have been made and a number of differences observed. The possibility that a portion of these activity differences may be due to random variability cannot be excluded since some differences were small. However, this possibility was minimized by analyzing relatively large populations and through the use of the experimental block design. In addition, the criterion of considering stocks significantly different for an enzyme activity only when both sexes were different further reduced the effects of random variability. In fact, it may have resulted in some true stock differences not being considered significant. Of those stock differences which were considered significant, there was no obvious explanation based upon the variant genes of these stocks for the two enzyme differences observed in comparisons among  $F_1$  stocks. However, there are some interesting speculations which can be made concerning observed differences between the  $F_1$  stocks and C57BL/6JNctr.

The large number of significant enzyme variants found in the BC10 $F_1$  and BC2 $F_1$  stocks may simply reflect the fact that the backcross markers in those strains carried a larger segment of chromosome from the donor strain to the recipient strain. The BC10 congenic stock contains variants at both *Np-1*



and *Es-10* on chromosome 14 which were linked and are 10 cM apart, with the entire length of this segment believed to be about 30 cM (Womack *et al.*, 1977). The BC2 congenic stock contains variants at *Amy-1*, *Amy-2* which were linked on chromosome 3, and at the *a*<sup>+</sup> allele on chromosome 2. Together these can be expected to encompass about 40 cM. There was an increased probability that the larger portion of donor genome of BC2 and BC10F<sub>1</sub> stocks carried additional non-C57BL/6J genes which can exert pleiotropic, heteromeric, or single gene effects upon the realization of measured enzymes.

The marker loci for the BC10 congenic stock were the *ES-10*<sub>c</sub> (esterase) and *NP-1*<sub>b</sub> (nucleoside phosphorylase) alleles on chromosome 14. Nucleoside phosphorylase catalyzes the phosphorolytic cleavage of adenosine, guanosine, inosine, and their deoxy analogues (Bergmeyer, 1974). It was therefore directly involved in the availability of ATP, GTP, etc. All of the affected enzymes (ATPase, STK, MDH, GIDH, CR, and FDP,Ald) either use ATP as a cofactor or substrate or were only one step removed from an ATP-requiring reaction in their respective pathways. The alteration at *NP-1* may have a pleiotropic effect upon the realization of the activity of several enzymes which were responsive to the availability of ATP. This speculation was supported by the association among activities of the enzymes ATPase, CR, MDH, and STK as noted by factor analysis. Although GIDH and FDP,Ald were one step removed from an ATP-requiring reaction, their lack of association with the other four enzymes or with each other suggests that additional, independent factors were involved.

The marker loci for the BC2 congenic stock were the *a* locus on chromosome 2 and the amylases on chromosome 3. Amylase was involved in the conversion of glycogen to maltose which, in turn, provides a source of D-glucose for entry into glycolysis. The alterations of *Amy-1*<sup>b</sup> or *Amy-2*<sup>b</sup> may account for the variant activity of FDP,Ald, which was a glycolytic enzyme. However, because the activities of AAO, GIDH, and GIK were associated with each other but not with the activity of FDP,Ald, at least two independent factors were required to account for the variant activities of BC2F<sub>1</sub>.

The marker locus for the BC7 congenic stock was the mitochondrial MDH, *Mor-1*<sup>b</sup> allele on chromosome 5. Only the activity of glutamate dehydrogenase differed between this stock and C57BL/6JNctr. No stock difference in MDH activity was observed. It seems improbable that the variant allele at the *Mor-1* locus would be responsible for GIDH activity change since its presence did not elicit clear activity response of its own product. In this case the genetic factor involved in the increase in activity of GIDH was probably one either linked to the *Mor-1*, heterozygous by chance, or the result of genetic drift.

The BC13 marker locus was the *b* allele at esterase 8 on chromosome 7. Again, GIDH activity was found to be different from that in C57BL/6JNctr.

GIDH variants relative to C57BL/6JNctr were found in the BC2, 7, 10, and 13 F<sub>1</sub>'s. The GIDH activity for BC6AF<sub>1</sub> was not significantly different from the C57BL/6JNctr in the females, although it was significant in the males and slightly increased in the females. It was not clear whether all the F<sub>1</sub> stocks carry a common gene variant relative to C57BL/6JNctr and BC6AF<sub>1</sub> was just an outlier of this population or whether the other four F<sub>1</sub> stocks each possess separate genetic factors associated with the variant markers which independently impact upon GIDH activity. It was anticipated that there should be more genetic differences resulting from the 20- to 40-cM segments from donor strains than might have occurred through genetic drift. If a gene resides on each variant segment which has a similar effect on GIDH activity, then this enzyme must be responsive to a variety of genetic factors involved in the control of synthesis of amino acids and other related functions in intermediary metabolism. We would consider this situation, where many genetic factors affect a control point enzyme, a heteromeric interaction. Alternatively, if divergence between the two C57BL/6J stocks has occurred such that one of them now possesses a genetic factor which affects GIDH activity, all of the F<sub>1</sub> stocks would be expected to differ from C57BL/6JNctr and exhibit approximately the same activity. The observation that GIDH activity was significantly increased over that of C57BL/6JNctr in males of all five F<sub>1</sub> stocks and females of four F<sub>1</sub> stocks, and even slightly increased in BC6AF<sub>1</sub> females, favors the probability that the GIDH differences may be the result of some new gene carried by either the C57BL/6J mice originally used to construct the homozygous congenic stocks or the C57BL/6JNctr mice used in the generation of the F<sub>1</sub> heterozygous stocks. GIDH from all the F<sub>1</sub> stocks and C57BL/6JNctr was analyzed using polyacrylamide gel electrophoresis and isoelectric focusing, and no mobility or isoelectric point differences were noted (data not shown). Although not conclusive, this provides evidence that the genetic factor responsible for the activity differences between C57BL/6JNctr and the four F<sub>1</sub> congenic stocks may not be at the structural gene. Regardless of whether genetic divergence or heteromeric effects of separate, independent genes account for the observed differences, the altered genetic factor responsible must be pleiotropically affecting GIDH activity.

Regulatory genes controlling enzyme synthesis are generally closely linked to their respective structural genes, while postranslational processing genes are typically not linked to their enzymes' structural genes (Paigen, 1979). Since the structural locus of the mapped enzymes having altered activities in the F<sub>1</sub> stocks is either not linked or not known to be linked to the donor portion of the genome, the variations in enzyme activity reported here are not anticipated to be the result of regulatory gene effects, but rather the result of posttranslational processing genes or similar modifying factors. Although the factors responsible for the altered enzyme activities observed in

this study can only be postulated, it is obvious that the activity of a realized enzyme is dependent upon genetic factors other than just the integrity of the structural gene.

## ACKNOWLEDGMENTS

We express our indebtedness to Dr. D. A. Casciano for his helpful suggestions, to Dr. J. E. Womack for his review of the manuscript, and to Mrs. Carolyn Phifer for her assistance in typing the manuscript.

## REFERENCES

- Bailey, D. W. (1977). Genetic drift: The problem and its possible solution by frozen-embryo storage. *Ciba Found. Symp.* **52**:291.
- Bergmeyer, H. U. (1974). Nucleoside phosphorylase. In *Methods of Enzymatic Analysis*, Academic Press, New York, Vol. 1, p. 490.
- Dizik, M., and Elliot, R. W. (1978). A second gene affecting the sialylation of lysosomal  $\alpha$ -mannosidase in mouse liver. *Biochem. Genet.* **16**:247.
- Festing, M. (1973). A multivariate analysis of subline divergences in the shape of the mandible in C57BL/Gr mice. *Genet. Res. Camb.* **21**:121.
- Feuers, R. J., Delongchamp, R. R., Casciano, D. A., Burkhart, J. G., and Mohrenweiser, H. W. (1980). Assay for mouse tissue enzymes: Levels of activity and statistical variation for 29 enzymes of liver or brain. *Anal. Biochem.* **101**:123.
- Hoi-Sen, Y. (1972). Is subline differentiation a continuing process in inbred strains of mice? *Genet. Res. Camb.* **19**:53.
- Kshirsagar, A. M. (1972). Regression and correlation among several variables. In *Multivariate Analysis*, Mercel-Dekker, New York, pp. 9-17.
- Lalley, P. A., and Shows, T. B. (1977). Lysosomal acid phosphatase deficiency: Liver specific variant in the mouse. *Genetics* **87**:305.
- Paigen, K. (1971). The genetics of enzyme realization (a review). In Recheigl, M. (eds.), *Enzyme Synthesis and Degradation in Mammalian Systems*, Karger, Basel, pp. 1-47.
- Paigen, K. (1979). Acid hydrolases as models of genetic control. *Annu. Rev. Genet.* **13**:417.
- Papaoannou, V. E., and Festing, M. F. W. (1980). Genetic drift in a stock of laboratory mice. *Lab. Anim.* **14**:11.
- Roderick, T. R., and Womack, J. E. (1981). Strains of mice congenic for electrophoretic markers (in preparation).
- Seal, H. L. (1968). Factor analysis. In *Multivariate Statistical Analysis for Biologists*, Methuen, London, pp. 153-180.
- Winer, B. J. (1971). Design and analysis of single-factor experiments. In *Statistical Principles in Experimental Design*, McGraw-Hill, New York, pp. 149-201.
- Womack, J. E., and Eicher, E. M. (1977). Liver specific lysosomal acid phosphatase deficiency (Apl) on mouse chromosome 17. *Mol. Gen. Genet.* **155**:315.
- Womack, J. E., Davisson, M. T., Eicher, E. M., and Kendall, D. A. (1977). Mapping of nucleoside phosphorylase (Np-1) and esterase-10 on mouse chromosome 14. *Biochem. Genet.* **15**:347.
- Womack, J. E., LuShun Yan, D., and Potier, M. (1981). Gene for neuraminidase activity on mouse chromosome 17 near H-2: Pleiotropic effect on multiple hydrolases. *Science* **212**(3):63.